Digital Breast Tomosynthesis Market

Digital Breast Tomosynthesis Market – Overview

The global digital breast tomosynthesis market is projected to expand at a promising rate from 2021 to 2031 (forecast period). Breast cancer is among the most frequent types of cancer in women, afflicting approximately 627,000 women worldwide in 2018. The global rate of survival varies according to the timing and rate of diagnosis and the availability and price of services. Globally, greater investment in R&D to provide improved cancer detection facilities has resulted in significant investment in the global digital breast tomosynthesis market. Moreover, growing health consciousness and technical improvements are expected to aid the global digital breast tomosynthesis market growth during the forecast period.

Digital Breast Tomosynthesis Market – Competitive Landscape

Prominent players in the global digital breast tomosynthesis market are Hologic Inc., Fujifilm Corporation, Ge Healthcare, Siemens Healthineers, PerkinElmer Inc., others. Participants' key strategies include product launches, mergers and acquisitions, joint ventures, and regional growth.

In August 2021, FUJIFILM Medical Systems stated that its ASPIRE Cristalle mammography system with digital breast tomosynthesis (DBT) now supports ScreenPoint Medical's new FDA-approved Transpara powered by Fusion AI for 2D and 3D mammography.

Digital Breast Tomosynthesis Market – Trends and Opportunities

One of the primary factors projected to boost the global digital breast tomosynthesis market is the increased global prevalence of breast cancer. As per the World Health Organization, 2.3 million women were affected with breast cancer in 2019. Digital breast tomosynthesis is a technology that allows for the three-dimensional restoration of breast tissue, which is then displayed as consecutive sections across the breast. It improves breast cancer detection while decreasing false-positive and recall rates. Moreover, it improves the identification of ductal carcinoma in situ, which are little abnormal tissue growths in the breast's milk ducts. When these tumors are eliminated at a preliminary phase, they seldom pose any harm to the patient, which is anticipated to propel the global digital breast tomosynthesis market.

Furthermore, the increased public awareness of the benefits of digital breast tomosynthesis and the rise in consumer healthcare expenditure is projected to support the global digital breast tomosynthesis market growth. Many organizations throughout the world are attempting to raise awareness of breast cancer medications. For example, in March 2020, the World Health Organization (WHO) held an awareness event called "Hearing the Call of Women with Breast Cancer" and announced their new Global Breast Cancer Campaign, which aims to reduce the global mortality rate by 2.5% per year until 2040. In Malaysia, the Breast Cancer Foundation has always been at the vanguard of disseminating knowledge about breast cancer and the most recent scientific developments in its treatments, empowerment, and support programs, which are expected to bolster the global digital breast tomosynthesis market.

Digital Breast Tomosynthesis Market – Regional Landscape

North America digital breast tomosynthesis market is projected to grow due to well-trained healthcare personnel, a well-developed healthcare infrastructure, a greater affordability rate, and an increase in the prevalence of breast cancer disease. Breast cancer is the most common type of cancer in women in the United States. One out of every eight American women (about 13%) may develop invasive breast cancer during their lives.

In Asia Pacific, the digital breast tomosynthesis market is expected to expand due to increased government initiatives to raise awareness about breast cancer treatment, investments by companies in emerging nations, increasing disposable income, and population growth in countries such as China and India. For example, as part of the 'Swasth Mahila, Swasth Goa' project, free breast cancer screening is provided to 1 lakh women in Goa, ensuring that 50% of the state's age-eligible female population is screened.